drugset / Trial / NCT07292688
Study of CM383 in Healthy Subjects
RandomizedParallel-groupOpen-labelTreatment
Summary
This study is a Phase I, single-center, randomized, open-label, parallel-controlled study, aimed at evaluating the pharmacokinetics, pharmacodynamics, immunogenicity, safety, and tolerability of a single dose of CM383 administered via intravenous infusion or subcutaneous injection in healthy male subjects.
Timeline
- Start
- 2026-01
- Primary completion
- 2026-07
- Completion
- 2026-07
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | CM383 | Unknown | — | Subcutaneous |
Indications
No indication recorded.